Abstract
To study the effect of thyrotropin-releasing hormone (TRH) and somatostatin (SRIF) on prolactin (PRL) secretion in at term human fetus these peptides have been administered to at term pregnant women during labor. Evidence has been reported that TRH and SRIF cross the placental barrier and affect the secretion of pituitary hormones. 400 μg TRH were administered to 37 pregnant women. As control 11 women received saline. In cord blood (CB) of neonates whose mothers received TRH CB PRL concentration was not different from those treated with saline, with values ranging between 192 ± 18 and 342 ± 48 ng/ml. 500 μg cyclic SRIF diluted in saline was infused over a period of 30 min in 55 women. Control subjects were infused with saline. At birth CB PRL concentration in SRIF treated neonates ranged between 266 ± 32 and 327 ± 48 ng/ml. In neonates whose mothers were treated with saline, CB PRL was 305 ± 31 ng/ml. This value was not significantly different from that in SRI F-treated groups. Our findings suggest that in at term human fetus TRH does not stimulate PRL secretion probably because fetal pituitary secretes PRL at maximal releasing activity. Furthermore SRIF administration does not have any effect on fetal PRL secretion as consistently observed in adults.
| Original language | English |
|---|---|
| Pages (from-to) | 521-524 |
| Number of pages | 4 |
| Journal | Journal of Endocrinological Investigation |
| Volume | 7 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1984 |
Fingerprint
Keywords
- fetus
- PRL
- SRIF
- TRH
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Absent prolactin (PRL) response to thyrotropin releasing hormone (TRH) and somatostatin (SRIF) in at term fetus. / Robuschi, G.; d’Amato, L.; Salvi, M.; Gardini, E.; Montermini, M.; Dall’Aglio, E.; Borciani, E.; Fontanesi, V.; Alboni, A.; Gnudi, A.; Roti, Elio.
In: Journal of Endocrinological Investigation, Vol. 7, No. 5, 1984, p. 521-524.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Absent prolactin (PRL) response to thyrotropin releasing hormone (TRH) and somatostatin (SRIF) in at term fetus
AU - Robuschi, G.
AU - d’Amato, L.
AU - Salvi, M.
AU - Gardini, E.
AU - Montermini, M.
AU - Dall’Aglio, E.
AU - Borciani, E.
AU - Fontanesi, V.
AU - Alboni, A.
AU - Gnudi, A.
AU - Roti, Elio
PY - 1984
Y1 - 1984
N2 - To study the effect of thyrotropin-releasing hormone (TRH) and somatostatin (SRIF) on prolactin (PRL) secretion in at term human fetus these peptides have been administered to at term pregnant women during labor. Evidence has been reported that TRH and SRIF cross the placental barrier and affect the secretion of pituitary hormones. 400 μg TRH were administered to 37 pregnant women. As control 11 women received saline. In cord blood (CB) of neonates whose mothers received TRH CB PRL concentration was not different from those treated with saline, with values ranging between 192 ± 18 and 342 ± 48 ng/ml. 500 μg cyclic SRIF diluted in saline was infused over a period of 30 min in 55 women. Control subjects were infused with saline. At birth CB PRL concentration in SRIF treated neonates ranged between 266 ± 32 and 327 ± 48 ng/ml. In neonates whose mothers were treated with saline, CB PRL was 305 ± 31 ng/ml. This value was not significantly different from that in SRI F-treated groups. Our findings suggest that in at term human fetus TRH does not stimulate PRL secretion probably because fetal pituitary secretes PRL at maximal releasing activity. Furthermore SRIF administration does not have any effect on fetal PRL secretion as consistently observed in adults.
AB - To study the effect of thyrotropin-releasing hormone (TRH) and somatostatin (SRIF) on prolactin (PRL) secretion in at term human fetus these peptides have been administered to at term pregnant women during labor. Evidence has been reported that TRH and SRIF cross the placental barrier and affect the secretion of pituitary hormones. 400 μg TRH were administered to 37 pregnant women. As control 11 women received saline. In cord blood (CB) of neonates whose mothers received TRH CB PRL concentration was not different from those treated with saline, with values ranging between 192 ± 18 and 342 ± 48 ng/ml. 500 μg cyclic SRIF diluted in saline was infused over a period of 30 min in 55 women. Control subjects were infused with saline. At birth CB PRL concentration in SRIF treated neonates ranged between 266 ± 32 and 327 ± 48 ng/ml. In neonates whose mothers were treated with saline, CB PRL was 305 ± 31 ng/ml. This value was not significantly different from that in SRI F-treated groups. Our findings suggest that in at term human fetus TRH does not stimulate PRL secretion probably because fetal pituitary secretes PRL at maximal releasing activity. Furthermore SRIF administration does not have any effect on fetal PRL secretion as consistently observed in adults.
KW - fetus
KW - PRL
KW - SRIF
KW - TRH
UR - http://www.scopus.com/inward/record.url?scp=0021714916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021714916&partnerID=8YFLogxK
U2 - 10.1007/BF03348461
DO - 10.1007/BF03348461
M3 - Article
VL - 7
SP - 521
EP - 524
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
SN - 0391-4097
IS - 5
ER -